A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 13 Jul 2017 Planned number of patients changed from 78 to 160.
- 07 Jul 2016 Planned primary completion date changed from 1 Aug 2024 to 1 Jul 2024.
- 07 Jul 2016 Status changed from not yet recruiting to recruiting.